Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Sub-lingual immunotherapy: world allergy organization position paper 2009

G Walter Canonica et al. World Allergy Organ J. 2009 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
No caption available.
SLIDE 1
SLIDE 1
History of sublingual immunotherapy.
See this image and copyright information in PMC

References

REFERENCES, PREFACE

    1. Lorenz AR, Lüttkopf D, Seitz R, Vieths S. The regulatory system in Europe with special emphasis on allergen products. Int Arch Allergy Immunol. 2008;147:263–275 - PubMed
    1. Guideline on Allergen Products. Production and quality issues. EMEA, CHMP/BWP/304831/2007 adopted by CHMP November 20, 2008.
    1. European Pharmacopoeia 6.6. Allergen products, 01/2010/1063.
    1. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317–324 - PubMed
    1. Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. EMEA, CHMP/EWP/18504/2006, adopted by CHMP November 20, 2008.

REFERENCES, CHAPTER 1

    1. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;i:1572–1573
    1. Curtis HH. The immunizing cure of hayfever. Med News (NY). 1900;77:16–18
    1. Black JH. The oral administration of pollen. J Lab Clin Med. 1927;12:1156
    1. Black JH. The oral administration of pollen: clinical report. J Lab Clin Med. 1928;13:709
    1. Herxeimer H. Bronchial hypersensitization and hyposensitization in man. Int Arch Allergy Appl Immunol. 1951;40:40–57 - PubMed

REFERENCES, CHAPTER 2

    1. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;i:1572–1573
    1. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911;ii:814–817 - PubMed
    1. Cohen SG, Evans R., III Allergen Immunotherapy in Historical Perspective. In: Lockey RF, Ledford DK, eds. Allergens and Allergen Immunotherapy. 4th ed New York: Informa Healthcare, 2008;1–29
    1. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med. 1965;273:675–679 - PubMed
    1. Norman PS, Winkenwerder WL, Lichtenstein LM. Immunotherapy of hay fever with antigen E: comparisons with whole pollen extract and placebo. J Allergy. 1968;42:93–108 - PubMed

REFERENCES, CHAPTER 3

    1. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006;61:151–165 - PubMed
    1. Novak N, Haberstok J, Bieber T, Allam J-P. The immune privilege of the oral mucosa. Trends Mol Med. 2008;14:191–198 - PubMed
    1. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172:3252–3259 - PubMed
    1. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth M.-T, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14677–14682 - PMC - PubMed
    1. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205–1214 - PubMed

REFERENCES, CHAPTER 4

    1. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317–324 - PubMed
    1. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy. 1986;16:483–491 - PubMed
    1. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol. 1990;18:277–284 - PubMed
    1. Nelson H, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol. 1993;92:229–236 - PubMed
    1. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double-blind placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994;49:309–313 - PubMed

REFERENCES, CHAPTER 5

    1. Cox LS, Larenas-Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021–1035 - PubMed
    1. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1–20 - PubMed
    1. Stewart GE, 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol. 1992;90:567– 578 - PubMed
    1. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy. 2006;61:1235. - PubMed
    1. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy. 2007;62:567–568 - PubMed

REFERENCES, CHAPTER 6

    1. Spergel JM. Atopic march: link to upper airways. Curr Opin Allergy Clin Immunol. 2005;5:17–21 - PubMed
    1. Guerra S, Sherrill DL, Baldacci S, Carrozzi L, Pistelli F, et al. Rhinitis is an independent risk factor for developing cough apart from colds among adults. Allergy. 2005;60:343–349 - PubMed
    1. Lombardi C, Passalacqua G, Gargioni S, Senna G, Ciprandi G, Scordamaglia A, et al. The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years. Respir Med. 2001;95:9–12 - PubMed
    1. Leynaert B, Neukirch C, Kony S, Guenegou A, Bousquet J, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004;113:86–93 - PubMed
    1. Toren K, Olin AC, Hellgren J, Hermansson BA. Rhinitis increases the risk for adult-onset asthma: a Swedish population-based case-control study (MAP-study). Respir Med. 2002;96:635–641 - PubMed

REFERENCES, CHAPTER 7

    1. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990;18:277–284 - PubMed
    1. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141–148 - PubMed
    1. Roder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008;19:197–207 - PubMed
    1. Larenas-Linnemann D. Sublingual immunotherapy in children: more optimism today. Pediatr Allergy Immunol. 2009;20:399–400 - PubMed
    1. Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61:1177–1183 - PubMed

REFERENCES, CHAPTER 8

    1. Current status of allergen immunotherapy Shortened version of a World Health Organisation/International Union of Immunological Societies Working Group Report. Lancet. 1989;1:259–261 - PubMed
    1. Malling H. Immunotherapy. Position Paper of the EAACI. Allergy. 1988;43(Suppl 6).
    1. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81:401–405 - PubMed
    1. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Bjorksten B, Bousquet J, et al. Local immunotherapy. Allergy. 1998;53:933–944 - PubMed
    1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl):S147–334 - PubMed

REFERENCES, CHAPTER 9

    1. Bousquet J, Lockey R, Malling H-J. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. J Allergy Clin Immunol. 1998;102:558–562 - PubMed
    1. Cox LS, Larenas-Linnemamm D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021–1035 - PubMed
    1. Canonica WG, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce the general validity of the results. Allergy. 2007;62:317–324 - PubMed
    1. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a metanalysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141–148 - PubMed
    1. Sopo SM, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child. 2004;89:620–624 - PMC - PubMed

REFERENCES, CHAPTER 10

    1. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16:802–807 - PubMed
    1. Ryan D, Grant-Casey J, Scadding G, Pereira S, Pinnock H, Sheikh A. Management of allergic rhinitis in UK primary care: baseline audit. Prim Care Respir J. 2005;14:204–209 - PMC - PubMed
    1. Ninan TK, Russell G. Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years art. BMJ. 1992;304:873–875 - PMC - PubMed
    1. Gupta R, Sheikh A, Strachan D, Anderson HR. Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions data. BMJ. 2003;327:1142–1143 - PMC - PubMed
    1. Haubrich WS. Medical meanings: a glossary of word origins (Book). ACP Press, 2004. ISBN: 1930513496, 9781930513495; page 10.

REFERENCES, CHAPTER 11

    1. Malling HJ. Sublingual immunotherapy: efficacy–methodology and outcome of clinical trials. Allergy. 2006;61(Suppl 81):24–28 - PubMed
    1. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60:4–12 - PubMed
    1. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141–148 - PubMed
    1. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133:599–609 - PubMed
    1. Roder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008;19:197–207 - PubMed